Nucleic Acid News and Research

RSS

Global anti-tuberculosis campaign now ‘at a crossroads’

Tuberculosis care and control has improved dramatically over the last two decades, but numbers of cases and deaths are still high and multidrug resistant-TB is an under-reported and ever-increasing problem, suggest findings from the World Health Organization Global TB Report 2012.

18 Oct 2012

Thermo Fisher Scientific introduces MYECL Imager instrument

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific MYECL Imager, an easy-to-use imaging instrument that delivers one-touch image capture and analysis of protein and nucleic acid gels and Western blots.

From Thermo Fisher Scientific Inc. 17 Oct 2012

Roche announces availability of new HIV-1 viral load test in the U.S.

Roche announced today the U.S. availability of a new HIV-1 viral load test based on the company's proprietary dual-target approach. The COBAS TaqMan HIV-1 Test v2.0 for use with the High Pure System enables labs to combine an FDA-approved process for manual specimen preparation with an automated real-time PCR analyzer for amplification and detection.

From Roche Sequencing and Life Science 4 Oct 2012

Thermo Fisher Scientific announces opening of Molecular Biology Center of Excellence in Lithuania

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its Molecular Biology Center of Excellence in Vilnius, Lithuania.

From Thermo Fisher Scientific Inc. 20 Sep 2012

DNA synthesis methods: an interview with Clemens Richert

Automated DNA synthesis has been around for almost three decades. The key difference between the established methodology for making oligodeoxynucleotides (short stretches of single-stranded DNA) and our method is the template strand.

7 Sep 2012

Akonni receives NSF's Phase 2 SBIR Grant to develop Lab-on-a-Film microarray

Akonni Biosystems, a life science tools / molecular diagnostics company that develops, manufactures, and plans to market molecular testing devices for diagnosing infectious diseases and human genetic disorders, announced today the receipt of a $498,780 Phase 2 SBIR Grant from the National Science Foundation (NSF).

6 Sep 2012

People with guanine version of rs55705857 SNP more likely to develop gliomas

People who carry a "G" instead of an "A" at a specific spot in their genetic code have roughly a six-fold higher risk of developing certain types of brain tumors, a Mayo Clinic and University of California, San Francisco study has found. The

27 Aug 2012

ACS National Meeting & Exposition focuses on DNA wires and their potential use in identifying diseases

In a discovery that defies the popular meaning of the word "wire," scientists have found that Mother Nature uses DNA as a wire to detect the constantly occurring genetic damage and mistakes that ― if left unrepaired ― can result in diseases like cancer and underpin the physical and mental decline of aging.

20 Aug 2012

Antisense therapy shows promise in treating toxoplasmosis

A targeted approach to treating toxoplasmosis, a parasitic disease, shows early promise in test-tube and animal studies, where it prevented the parasites from making selected proteins. When tested in newly infected mice, it reduced the number of viable parasites by more than 90 percent, researchers from the University of Chicago Medicine report in the Proceedings of the National Academy of Sciences.

14 Aug 2012

Roche MagNA Pure 96 System's CE certified IVD version launched

Today, Roche announced the launch of its new CE certified IVD version of the MagNA Pure 96 System for automated sample preparation. By providing a maximum of lot-to-lot consistency and highest quality, the new MagNA Pure 96 System is designed to even better fulfill the needs of diagnostic customers. In 2011, the IVD version of MagNA Pure 96 was already introduced in the US.

From Roche Sequencing and Life Science 13 Aug 2012

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

26 Jul 2012

Roche now offers expanded portfolio of blood screening solutions

Roche announced today that it now offers an expanded portfolio of blood screening solutions with an integrated serology testing offering.

25 Jul 2012

PAMAM G-3 actually prevents activation of the process that leads to thrombosis

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges -- stopping the formation of blood clots without triggering equally threatening bleeding.

24 Jul 2012

Targeted regulation of microRNA-125b may lead to effective prostate cancer therapies

A small, naturally occurring nucleic acid sequence, called a microRNA, known to regulate a number of different cancers, appears to alter the activity of the androgen receptor, which plays a critical role in prostate cancer.

18 Jul 2012

Luminex to acquire molecular diagnostics company, GenturaDx

Luminex Corporation today announced a definitive agreement to acquire privately-held, GenturaDx, a molecular diagnostics company focused on making nucleic acid testing both affordable and practical for any laboratory. GenturaDx is in late stage development of a fully integrated, highly automated, real-time PCR system that employs a single-use cassette for true sample-to-answer workflow.

From Luminex 9 Jul 2012